Search Icon


Drug Information

Product NDC: 0002-7724

Proprietary Name: TALTZ

Non Proprietary Name: ixekizumab

Active Ingredient(s):
  • 80 mg/mL IXEKIZUMAB

Administration Route(s): SUBCUTANEOUS


Pharmacy Class(es):
  • Interleukin-17A Antagonist [EPC];
  • Interleukin-17A Antagonists [MoA]

Labeler Information

Labeler Name: Eli Lilly and Company
FDA Application Number: BLA125521
Marketing Category: BLA
Start Marketing Date:3/22/2016

Package Information

No. Package Code Package Description Billing Unit
10002-7724-111 SYRINGE in 1 CARTON (0002-7724-11) / 1 mL in 1 SYRINGE (0002-7724-01)ML
20002-7724-991 SYRINGE in 1 CARTON (0002-7724-99) / 1 mL in 1 SYRINGE

NDC Record

Field Name Field Value Definition
PRODUCT NDC0002-7724The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMETALTZThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEixekizumabThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMEINJECTION, SOLUTIONThe translation of the dosage form Code submitted by the firm.
ROUTE NAMESUBCUTANEOUSThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE3/22/2016This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEBLAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at under Structured Product Labeling Resources.
APPLICATION NUMBERBLA125521This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEEli Lilly and CompanyName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEIXEKIZUMABAn active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
PHARM CLASSESInterleukin-17A Antagonist [EPC], Interleukin-17A Antagonists [MoA] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 2/1/2023